From Circuits to Symptoms: Advances in Psychiatry and Brain Science

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropsychiatry".

Deadline for manuscript submissions: 10 July 2026 | Viewed by 2488

Special Issue Editor


E-Mail Website
Guest Editor
North Islington Core Team, Academic Secretary RCPsych, London N7 8US, UK
Interests: clinical research; patients’ outcome; depression and inflammation; PTSD; psychosis; addiction; dual diagnosis; metabolism; antipsychotics

Special Issue Information

Dear Colleagues,

This Special Issue entitled "From Circuits to Symptoms: Advances in Psychiatry and Brain Science" highlights recent progress at the intersection of brain science and mental health. Driven by innovations in neuroimaging, molecular biology, genetics, and computational modelling, researchers and clinicians are gaining deeper insights into the brain’s structure, function, and dysfunction.

This Special Issue brings together original research articles, reviews, and perspectives that reflect the diversity and dynamism of the field. Topics include emerging biomarkers for psychiatric disorders, novel therapeutic strategies such as neuromodulation and psychedelic-assisted therapy, the role of neuroinflammation and the gut–brain axis, advances in digital psychiatry and artificial intelligence, and also some interesting new insights into phenomenology and psychopathology.

By showcasing both translational and clinical research, this collection aims to foster a more integrated understanding of mental illness and brain function, promoting a future where diagnostics and treatments are more precise, personalized, and biologically informed. We hope this Special Issue will serve as a valuable resource for clinicians, researchers, and students committed to advancing brain and mental health.

Dr. Stefania Bonaccorso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurosciences
  • mental health
  • biomarkers
  • inflammation
  • AI
  • digital psychiatry
  • phenomenology
  • psychopathology
  • psychedelics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1163 KB  
Article
Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
by Stefania Chiappini, John Martin Corkery, Amira Guirguis, Alessio Mosca, Mya Murray, Davide Arillotta, Luigi Dattoli, Giovanni Martinotti, Stefania Bonaccorso, Fabrizio Schifano and Nicolò Schifano
Brain Sci. 2026, 16(4), 394; https://doi.org/10.3390/brainsci16040394 - 4 Apr 2026
Viewed by 2083
Abstract
Background/Objectives: Finasteride and dutasteride are 5α-reductase inhibitors that block the conversion of testosterone to dihydrotestosterone, reducing androgenic stimulation of tissues such as the prostate and hair follicles. Used mainly for benign prostatic hyperplasia and androgenic alopecia, finasteride selectively inhibits type-2 5α-reductase isoenzyme, [...] Read more.
Background/Objectives: Finasteride and dutasteride are 5α-reductase inhibitors that block the conversion of testosterone to dihydrotestosterone, reducing androgenic stimulation of tissues such as the prostate and hair follicles. Used mainly for benign prostatic hyperplasia and androgenic alopecia, finasteride selectively inhibits type-2 5α-reductase isoenzyme, while dutasteride inhibits both type-1 and type-2. Although sexual adverse effects like erectile dysfunction are well-documented, emerging evidence suggests possible neuropsychiatric reactions—including depression, suicidal ideation, and cognitive decline—potentially linked to reduced neurosteroid synthesis, such as that of allopregnanolone. Causality cannot be inferred from spontaneous reporting data. This study aimed to assess pharmacovigilance signals for psychopathological disorders associated with finasteride and dutasteride in the FAERS database. Methods: Cleaned FAERS data referring to years up to 2025 after deduplication were analyzed, excluding non-serious cases and those without the drug as the sole suspect (MedDra 29.0). Reporting Odds Ratios (RORs) with 95% CIs were calculated to compare psychiatric reactions between finasteride and dutasteride. Python 3.11 was used to screen and summarize relevant cases, accounting for differences in total case numbers. Results: This pharmacovigilance study analyzed FAERS data to assess the neuropsychiatric and sexual adverse reactions associated with finasteride and dutasteride. Depression, anxiety, suicidality, and libido-related issues were reported more frequently for finasteride, especially in younger men using low-dose therapy for alopecia. Potential mechanisms include reduced neurosteroid synthesis, androgen/sex-hormone axis disruption, altered hippocampal neurogenesis, and dopaminergic changes. Conclusions: A baseline psychiatric assessment and the regular monitoring of mood, sexual function, and suicidal ideation are recommended. Limitations include under-reporting, reporting bias, and a lack of incidence data. The findings underscore the need for ongoing surveillance and controlled studies to clarify the clinical significance of these signals. Full article
(This article belongs to the Special Issue From Circuits to Symptoms: Advances in Psychiatry and Brain Science)
Show Figures

Figure 1

Back to TopTop